1
|
Talbot J, Tassart M, Aveline C, Kerrou K, Zhang Yin J, Périé S, Wagner I, Bennis M, Baujat B, Montravers F. Détection des parathyroïdes anormales : la TEP/TDM 18F-fluorocholine préalable améliore la sensibilité de l’échographie ; analyse de 300 examens pratiqués par le même échographiste. Médecine Nucléaire 2023. [DOI: 10.1016/j.mednuc.2023.01.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/06/2023]
|
2
|
Mauz-Körholz C, Landman-Parker J, Fernández-Teijeiro A, Attarbaschi A, Balwierz W, Bartelt JM, Beishuizen A, Boudjemaa S, Cepelova M, Ceppi F, Claviez A, Daw S, Dieckmann K, Fosså A, Gattenlöhner S, Georgi T, Hjalgrim LL, Hraskova A, Karlén J, Kurch L, Leblanc T, Mann G, Montravers F, Pears J, Pelz T, Rajić V, Ramsay AD, Stoevesandt D, Uyttebroeck A, Vordermark D, Körholz D, Hasenclever D, Wallace WH, Kluge R. Response-adapted omission of radiotherapy in children and adolescents with early-stage classical Hodgkin lymphoma and an adequate response to vincristine, etoposide, prednisone, and doxorubicin (EuroNet-PHL-C1): a titration study. Lancet Oncol 2023; 24:252-261. [PMID: 36858722 DOI: 10.1016/s1470-2045(23)00019-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2022] [Revised: 01/10/2023] [Accepted: 01/16/2023] [Indexed: 03/02/2023]
Abstract
BACKGROUND Children and adolescents with early-stage classical Hodgkin lymphoma have a 5-year event-free survival of 90% or more with vincristine, etoposide, prednisone, and doxorubicin (OEPA) plus radiotherapy, but late complications of treatment affect survival and quality of life. We investigated whether radiotherapy can be omitted in patients with adequate morphological and metabolic responses to OEPA. METHODS The EuroNet-PHL-C1 trial was designed as a titration study and recruited patients at 186 hospital sites across 16 European countries. Children and adolescents with newly diagnosed stage IA, IB, and IIA classical Hodgkin lymphoma younger than 18 years of age were assigned to treatment group 1 to be treated with two cycles of OEPA (vincristine 1·5 mg/m2 intravenously, capped at 2 mg, on days 1, 8, and 15; etoposide 125 mg/m2 intravenously, on days 1-5; prednisone 60 mg/m2 orally on days 1-15; and doxorubicin 40 mg/m2 intravenously on days 1 and 15). If no adequate response (a partial morphological remission or greater and PET negativity) had been achieved after two cycles of OEPA, involved-field radiotherapy was administered at a total dose of 19·8 Gy (usually in 11 fractions of 1·8 Gy per day). The primary endpoint was event-free survival. The primary objective was maintaining a 5-year event-free survival rate of 90% in patients with an adequate response to OEPA without radiotherapy. We performed intention-to-treat and per-protocol analyses. The trial was registered at ClinicalTrials.gov (NCT00433459) and with EUDRACT, (2006-000995-33) and is completed. FINDINGS Between Jan 31, 2007, and Jan 30, 2013, 2131 patients were registered and 2102 patients were enrolled onto EuroNet-PHL-C1. Of these 2102 patients, 738 with early-stage disease were allocated to treatment group 1. Median follow-up was 63·3 months (IQR 60·1-69·8). We report on 714 patients assigned to and treated on treatment group 1; the intention-to-treat population comprised 713 patients with 323 (45%) male and 390 (55%) female patients. In 440 of 713 patients in the intention-to-treat group who had an adequate response and did not receive radiotherapy, 5-year event-free survival was 86·5% (95% CI 83·3-89·8), which was less than the 90% target rate. In 273 patients with an inadequate response who received radiotherapy, 5-year event-free survival was 88·6% (95% CI 84·8-92·5), for which the 95% CI included the 90% target rate. The most common grade 3-4 adverse events were neutropenia (in 597 [88%] of 680 patients) and leukopenia (437 [61%] of 712). There were no treatment-related deaths. INTERPRETATION On the basis of all the evidence, radiotherapy could be omitted in patients with early-stage classical Hodgkin lymphoma and an adequate response to OEPA, but patients with risk factors might need more intensive treatment. FUNDING Deutsche Krebshilfe, Elternverein für Krebs-und leukämiekranke Kinder, Gießen, Kinderkrebsstiftung Mainz of the Journal Oldtimer Markt, Tour der Hoffnung, Menschen für Kinder, Mitteldeutsche Kinderkrebsforschung, Programme Hospitalier de Recherche Clinique, and Cancer Research UK.
Collapse
Affiliation(s)
| | - Judith Landman-Parker
- Department of Paediatric Haematology-Oncology, Sorbonne Université and Assistance Publique des Hopitaux de Paris, Hôpital a Trousseau, Paris, France
| | | | - Andishe Attarbaschi
- Department of Paediatric Haematology and Oncology, Medical University of Vienna, Vienna, Austria
| | - Walentyna Balwierz
- Department of Paediatric Oncology and Haematology, Institute of Paediatrics, Jagiellonian University Medical College, Krakow, Poland
| | - Jörg M Bartelt
- Department of Radiology, University Hospital Halle, Halle, Germany
| | - Auke Beishuizen
- Princess Máxima Centre for Paediatric Oncology, Utrecht and Erasmus, Sophia Children's Hospital, Rotterdam, Netherlands
| | - Sabah Boudjemaa
- Department of Pathology, Armand Trousseau Hospital, Paris, France
| | - Michaela Cepelova
- Department of Paediatric Haematology and Oncology, University Hospital Motol, Prague, Czech Republic
| | - Francesco Ceppi
- Pediatric Hematology-Oncology Unit, Division of Pediatrics, Department Woman-Mother-Child, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland
| | - Alexander Claviez
- Department of Paediatrics, University of Schleswig-Holstein, Kiel, Germany
| | - Stephen Daw
- Children and Young People's Cancer Service, University College Hospital London, London, UK
| | - Karin Dieckmann
- Strahlentherapie Allgemeines Krankenhaus Wien, Medizinische Universitätsklinik Wien, Vienna, Austria
| | | | | | - Thomas Georgi
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
| | - Lisa L Hjalgrim
- Department of Paediatrics and Adolescent Medicine, The Juliane Marie Centre, University Hospital Rigshospitalet, Copenhagen, Denmark
| | - Andrea Hraskova
- Department of Paediatric Haematology and Oncology, National Institute of Children's Disease and Comenius University, Bratislava, Slovakia
| | - Jonas Karlén
- Department of Paediatric Oncology at Astrid Lindgrens Children's Hospital, Karolinska University Hospital, Stockholm, Sweden
| | - Lars Kurch
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
| | - Thierry Leblanc
- Service d'Hématologie Pédiatrique, Hôpital Robert-Debré, Paris, France
| | - Georg Mann
- St Anna Children's Hospital, Medical University of Vienna, Vienna, Austria
| | - Francoise Montravers
- Department of Nuclear Medicine, Tenon Hospital, APHP and Sorbonne Université, Paris, France
| | - Jane Pears
- Our Lady's Hospital for Children's Health, Dublin, Ireland
| | - Tanja Pelz
- Medical Faculty (Prof C Mauz-Körholz) and Department of Radiation Oncology, Martin Luther University Halle-Wittenberg, Halle, Germany
| | - Vladan Rajić
- Clinical Department of Paediatric Haematology, Oncology, and Stem Cell Transplantation, University Medical Centre Ljubljana and University Children's Hospital, Ljubljana, Slovenia
| | - Alan D Ramsay
- Department of Cellular Pathology, University College Hospital London, London, UK
| | | | - Anne Uyttebroeck
- Paediatric Haematology and Oncology, Department of Oncology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
| | - Dirk Vordermark
- Medical Faculty (Prof C Mauz-Körholz) and Department of Radiation Oncology, Martin Luther University Halle-Wittenberg, Halle, Germany
| | - Dieter Körholz
- Department of Paediatric Oncology, Justus-Liebig-University Giessen, Giessen, Germany
| | - Dirk Hasenclever
- Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany
| | - William H Wallace
- Department of Paediatric Haematology and Oncology, Royal Hospital for Children and Young People, University of Edinburgh, Edinburgh, UK.
| | - Regine Kluge
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
| |
Collapse
|
3
|
Mauz-Körholz C, Landman-Parker J, Balwierz W, Ammann RA, Anderson RA, Attarbaschi A, Bartelt JM, Beishuizen A, Boudjemaa S, Cepelova M, Claviez A, Daw S, Dieckmann K, Fernández-Teijeiro A, Fosså A, Gattenlöhner S, Georgi T, Hjalgrim LL, Hraskova A, Karlén J, Kluge R, Kurch L, Leblanc T, Mann G, Montravers F, Pears J, Pelz T, Rajić V, Ramsay AD, Stoevesandt D, Uyttebroeck A, Vordermark D, Körholz D, Hasenclever D, Wallace WH. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. Lancet Oncol 2022; 23:125-137. [PMID: 34895479 PMCID: PMC8716340 DOI: 10.1016/s1470-2045(21)00470-8] [Citation(s) in RCA: 44] [Impact Index Per Article: 22.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2021] [Revised: 08/02/2021] [Accepted: 08/05/2021] [Indexed: 12/30/2022]
Abstract
BACKGROUND Children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma achieve an event-free survival at 5 years of about 90% after treatment with vincristine, etoposide, prednisone, and doxorubicin (OEPA) followed by cyclophosphamide, vincristine, prednisone, and procarbazine (COPP) and radiotherapy, but long-term treatment effects affect survival and quality of life. We aimed to investigate whether radiotherapy can be omitted in patients with morphological and metabolic adequate response to OEPA and whether modified consolidation chemotherapy reduces gonadotoxicity. METHODS Our study was designed as a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial, and was carried out at 186 hospital sites across 16 European countries. Children and adolescents with newly diagnosed intermediate-stage (treatment group 2) and advanced-stage (treatment group 3) classical Hodgkin lymphoma who were younger than 18 years and stratified according to risk using Ann Arbor disease stages IIAE, IIB, IIBE, IIIA, IIIAE, IIIB, IIIBE, and all stages IV (A, B, AE, and BE) were included in the study. Patients with early disease (treatment group 1) were excluded from this analysis. All patients were treated with two cycles of OEPA (1·5 mg/m2 vincristine taken intravenously capped at 2 mg, on days 1, 8, and 15; 125 mg/m2 etoposide taken intravenously on days 1-5; 60 mg/m2 prednisone taken orally on days 1-15; and 40 mg/m2 doxorubicin taken intravenously on days 1 and 15). Patients were randomly assigned to two (treatment group 2) or four (treatment group 3) cycles of COPP (500 mg/m2 cyclophosphamide taken intravenously on days 1 and 8; 1·5 mg/m2 vincristine taken intravenously capped at 2 mg, on days 1 and 8; 40 mg/m2 prednisone taken orally on days 1 to 15; and 100 mg/m2 procarbazine taken orally on days 1 to 15) or COPDAC, which was identical to COPP except that 250 mg/m2 dacarbazine administered intravenously on days 1 to 3 replaced procarbazine. The method of randomisation (1:1) was minimisation with stochastic component and was centrally stratified by treatment group, country, trial sites, and sex. The primary endpoint was event-free survival, defined as time from treatment start until the first of the following events: death from any cause, progression or relapse of classical Hodgkin lymphoma, or occurrence of secondary malignancy. The primary objectives were maintaining 90% event-free survival at 5 years in patients with adequate response to OEPA treated without radiotherapy and to exclude a decrease of 8% in event-free survival at 5 years in the embedded COPDAC versus COPP randomisation to show non-inferiority of COPDAC. Efficacy analyses are reported per protocol and safety in the intention-to-treat population. The trial is registered with ClinicalTrials.gov (trial number NCT00433459) and EUDRACT (trial number 2006-000995-33), and is closed to recruitment. FINDINGS Between Jan 31, 2007, and Jan 30, 2013, 2102 patients were recruited. 737 (35%) of the 2102 recruited patients were in treatment group 1 (early-stage disease) and were not included in our analysis. 1365 (65%) of the 2102 patients were in treatment group 2 (intermediate-stage disease; n=455) and treatment group 3 (advanced-stage disease; n=910). Of these 1365, 1287 (94%) patients (435 [34%] of 1287 in treatment group 2 and 852 [66%] of 1287 in treatment group 3) were included in the titration trial per-protocol analysis. 937 (69%) of 1365 patients were randomly assigned to COPP (n=471) or COPDAC (n=466) in the embedded trial. Median follow-up was 66·5 months (IQR 62·7-71·7). Of 1287 patients in the per-protocol group, 514 (40%) had an adequate response to treatment and were not treated with radiotherapy (215 [49%] of 435 in treatment group 2 and 299 [35%] of 852 in treatment group 3). 773 (60%) of 1287 patients with inadequate response were scheduled for radiotherapy (220 [51%] of 435 in the treatment group 2 and 553 [65%] of 852 in treatment group 3. In patients who responded adequately, event-free survival rates at 5 years were 90·1% (95% CI 87·5-92·7). event-free survival rates at 5 years in 892 patients who were randomly assigned to treatment and analysed per protocol were 89·9% (95% CI 87·1-92·8) for COPP (n=444) versus 86·1% (82·9-89·4) for COPDAC (n=448). The COPDAC minus COPP difference in event-free survival at 5 years was -3·7% (-8·0 to 0·6). The most common grade 3-4 adverse events (intention-to-treat population) were decreased haemoglobin (205 [15%] of 1365 patients during OEPA vs 37 [7%] of 528 treated with COPP vs 20 [2%] of 819 treated with COPDAC), decreased white blood cells (815 [60%] vs 231 [44%] vs 84 [10%]), and decreased neutrophils (1160 [85%] vs 223 [42%] vs 174 [21%]). One patient in treatment group 2 died of sepsis after the first cycle of OEPA; no other treatment-related deaths occurred. INTERPRETATION Our results show that radiotherapy can be omitted in patients who adequately respond to treatment, when consolidated with COPP or COPDAC. COPDAC might be less effective, but is substantially less gonadotoxic than COPP. A high proportion of patients could therefore be spared radiotherapy, eventually reducing the late effects of treatment. With more refined criteria for response assessment, the number of patients who receive radiotherapy will be further decreased. FUNDING Deutsche Krebshilfe, Elternverein für Krebs-und leukämiekranke Kinder Gießen, Kinderkrebsstiftung Mainz, Tour der Hoffnung, Menschen für Kinder, Programme Hospitalier de Recherche Clinique, and Cancer Research UK.
Collapse
Affiliation(s)
- Christine Mauz-Körholz
- Department of Paediatric Oncology, Justus-Liebig- University Giessen, Giessen, Germany; Medical Faculty, Martin Luther University Halle-Wittenberg, Halle, Germany
| | - Judith Landman-Parker
- Department of Paediatric Haematology-Oncology, Sorbonne Université and APHP-SIRIC CURAMUS Hôpital a Trousseau, Paris, France
| | - Walentyna Balwierz
- Department of Paediatric Oncology and Haematology, Institute of Paediatrics, Jagiellonian University Medical College, Krakow, Poland
| | - Roland A Ammann
- Paediatric Haematology and Oncology, Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, Bern Switzerland
| | - Richard A Anderson
- MRC Centre for Reproductive Health, Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK
| | - Andische Attarbaschi
- Department of Paediatric Haematology and Oncology, Medical University of Vienna, Vienna, Austria
| | - Jörg M Bartelt
- Department of Radiology, University Hospital Halle, Halle, Germany
| | - Auke Beishuizen
- Princess Máxima Centre for Paediatric Oncology, Utrecht and Erasmus, Sophia Children's Hospital, Rotterdam, The Netherlands
| | - Sabah Boudjemaa
- Department of Pathology, Armand Trousseau Hospital, Paris, France
| | - Michaela Cepelova
- Department of Paediatric Haematology and Oncology, University Hospital Motol, Prague, Czech Republic
| | - Alexander Claviez
- Department of Paediatrics, University of Schleswig-Holstein, Kiel, Germany
| | - Stephen Daw
- Children and Young People's Cancer Service, University College Hospital London, London, UK
| | - Karin Dieckmann
- Strahlentherapie AKH Wien Medizinische, Universitätsklinik Wien, Vienna, Austria
| | | | | | | | - Thomas Georgi
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
| | - Lisa L Hjalgrim
- Department of Paediatrics and Adolescent Medicine, The Juliane Marie Centre, University Hospital Rigshospitalet, Copenhagen, Denmark
| | - Andrea Hraskova
- Department of Paediatric Haematology and Oncology, National Institute of Children's Disease and Comenius University, Bratislava, Slovakia
| | - Jonas Karlén
- Department of Paediatric Oncology at Astrid Lindgrens Children's Hospital, Karolinska University Hospital, Stockholm, Sweden
| | - Regine Kluge
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
| | - Lars Kurch
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
| | - Thiery Leblanc
- Service d'Hématologie Pédiatrique, Hôpital Robert-Debré, Paris, France
| | - Georg Mann
- St Anna Children's Hospital, Medical University of Vienna, Vienna, Austria
| | - Francoise Montravers
- Department of Nuclear Medicine, Tenon Hospital, APHP and Sorbonne Université, Paris, France
| | - Jean Pears
- Our Lady's Hospital for Children's Health, Dublin, Ireland
| | - Tanja Pelz
- Department of Radiation Oncology, Martin Luther University Halle-Wittenberg, Halle, Germany
| | - Vladan Rajić
- Clinical Department of Paediatric Haematology, Oncology, and Stem Cell Transplantation, University Medical Centre Ljubljana and University Children's Hospital, Ljubljana, Slovenia
| | - Alan D Ramsay
- Department of Cellular Pathology, University College Hospital London, London, UK
| | | | - Anne Uyttebroeck
- Paediatric Haematology and Oncology, Department of Oncology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
| | - Dirk Vordermark
- Department of Radiation Oncology, Martin Luther University Halle-Wittenberg, Halle, Germany
| | - Dieter Körholz
- Department of Paediatric Oncology, Justus-Liebig- University Giessen, Giessen, Germany
| | - Dirk Hasenclever
- Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany
| | - William Hamish Wallace
- Department of Paediatric Haematology and Oncology, Royal Hospital for Children and Young People and University of Edinburgh, Edinburgh, UK.
| |
Collapse
|
4
|
Rammaert B, Maunoury C, Rabeony T, Alfandari S, Berger P, Rubio M, Braun T, Correas J, Montravers F, Lortholary O. Intérêt de la TEP-TDM dans le suivi des patients d’hématologie atteints de candidose chronique disséminée. Med Mal Infect 2020. [DOI: 10.1016/j.medmal.2020.06.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
5
|
Ohnona J, Nataf V, Gauthe M, Balogova S, Belissant Benesty O, Zhang-Yin J, Talbot JN, Montravers F. Prognostic value of functional tumor burden on 68Ga-DOTATOC PET/CT in patients with pancreatic neuro-endocrine tumors. Neoplasma 2019; 66:140-148. [PMID: 30509093 DOI: 10.4149/neo_2018_180328n209] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2018] [Accepted: 06/08/2018] [Indexed: 11/08/2022]
Abstract
Despite their relative quiescence, pancreatic neuro-endocrine tumors (pNET) can correspond to various presentations and outcomes. Several prognostic factors have been identified, including maximal standardized uptake value of the most intense focus (maxSUVmax) on Positron Emission Tomography (PET) with a somatostatin analogue. Herein, we investigate the prognostic value on progression free-survival of the total functional tumor volume (TFTV) measured by 68Ga-DOTATOC PET. From patients who underwent 68Ga-DOTATOC PET from 2008 to 2014, we selected consecutive patients with G1 or G2 pNET (2010 World Health Organization classification), at least one abnormal focus on PET and available follow-up data. TFTV was computed by summing the volumes of all pathological foci, delineated use of 41% of its SUVmax for each threshold focus. Fifty patients were included. During the follow-up period, 33 patients had stable or responsive disease (66%; median duration 28.5 months; range 6.3-77.7 months) and 17 patients experienced disease progression (34%; median progression time 21 months; range 6.7-44.7 months). Median PFS was 43.5 months. The best TFTV cut-off for predicting progression within 24 months was 13.8 cm3. Multivariate analysis determined that TFTV greater than 13.8 cm3 was the only criterion considered a significant risk factor for tumor progression (HR 2.9; p=0.0003). A significant difference in PFS was observed for TFTV (<13.8 vs. ≥ 13.8 cm3: median not reached vs. 25 months; p=0.0001). Our study suggests that 68Ga-DOTATOC TFTV measured on PET images is a valuable prognostic biomarker in patients with well-differentiated pNETs of all stages.
Collapse
Affiliation(s)
- J Ohnona
- Department of Nuclear Medicine, Hopitaux Universitaires Est Parisien, AP-HP Hopital TENON, Universite Sorbonne, Paris, France
| | - V Nataf
- Department of Nuclear Medicine, Hopitaux Universitaires Est Parisien, AP-HP Hopital TENON, Universite Sorbonne, Paris, France
| | - M Gauthe
- Department of Nuclear Medicine, Hopitaux Universitaires Est Parisien, AP-HP Hopital TENON, Universite Sorbonne, Paris, France
| | - S Balogova
- Department of Nuclear Medicine, Faculty of Medicine, Comenius University and St. Elisabeth Oncology Institute, Bratislava, Slovakia.,Department of Nuclear Medicine, Hopitaux Universitaires Est Parisien, AP-HP Hopital TENON, Universite Sorbonne, Paris, France
| | - O Belissant Benesty
- Department of Nuclear Medicine, Hopitaux Universitaires Est Parisien, AP-HP Hopital TENON, Universite Sorbonne, Paris, France
| | - J Zhang-Yin
- Department of Nuclear Medicine, Hopitaux Universitaires Est Parisien, AP-HP Hopital TENON, Universite Sorbonne, Paris, France
| | - J N Talbot
- Department of Nuclear Medicine, Hopitaux Universitaires Est Parisien, AP-HP Hopital TENON, Universite Sorbonne, Paris, France
| | - F Montravers
- Department of Nuclear Medicine, Hopitaux Universitaires Est Parisien, AP-HP Hopital TENON, Universite Sorbonne, Paris, France
| |
Collapse
|
6
|
Abstract
By means of the retrospective study of the clinical records of 158 women followed for breast cancer, we aimed to evaluate the consequences of a non-systematic indication for bone scan (BS) based either on CA 15-3 levels alone or a combination of tumor marker levels and clinical criteria. With the first option, the negative predictive value was 95% and 82% of the BS would have been avoided. With the second option, the negative predictive value was 97% and 59% of the BS would have been avoided. Furthermore, the preliminary results of a longitudinal study showed that those patients with normal CA 15-3 levels and positive bone scans showed a subsequent rise in CA 15-3 levels which frequently became elevated with an average delay of 15 months. Omission of systematic bone scans in the follow-up of breast cancer patients is likely to lead to a delay in the diagnosis of bone metastasis in 3% to 5%, the consequences of which have to be examined carefully.
Collapse
Affiliation(s)
- N Younsi
- Service de Médecine Nucléaire, Hôpital Tenon, Paris, France
| | | | | | | | | | | | | |
Collapse
|
7
|
Gendreau V, Montravers F, Philippe C, Talbot JN. Reevaluation of the Usefulness of Systematic Bone Scanning in Initial Staging and follow-up of Small Cell Lung Carcinoma, Taking into Account the Serum Levels of Neuron-Specific Enolase. Int J Biol Markers 2018; 12:148-53. [PMID: 9582603 DOI: 10.1177/172460089701200402] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The prescription of bone scans (BS) in the initial staging and follow-up of small cell lung carcinoma (SCLC) is a traditional attitude. The availability of the serum neuron-specific enolase (NSE) assay and budget limitations led us to evaluate retrospectively, in 57 patients, the consequences of a more selective attitude, namely to perform BS only in those patients with abnormal serum NSE levels. Both BS and NSE assays were performed in 47 patients referred for initial staging of SCLC; NSE levels were normal in 8 but in 2 of these cases (25%) secondary bone localizations with great clinical significance were discovered at BS. During follow-up, 59 BS were performed in conjunction with NSE assays; 45 NSE levels were in the normal range whereas 17 (38%) corresponding BS were suggestive of bone metastases. In conclusion, due to the frequent occurrence of false-negative results in patients with bone metastases, serum NSE levels proved to be useless in the selection for BS of patients suffering from SCLC.
Collapse
Affiliation(s)
- V Gendreau
- Services de Médecine Nucléaire, Hôpital Tenon, Paris, France
| | | | | | | |
Collapse
|
8
|
Testart Dardel N, Montravers F, Triviño-Ibañez E, Gauthé M, Houry S, Talbot JN. Best sensitivity of 18F-FDOPA PET/CT to detect metastasis in one case of neuroendocrine tumour of the ileum. Rev Esp Med Nucl Imagen Mol 2016; 35:402-405. [PMID: 27246293 DOI: 10.1016/j.remn.2016.04.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2016] [Revised: 04/08/2016] [Accepted: 04/12/2016] [Indexed: 11/18/2022]
Abstract
Neuroendocrine tumours (NET) are heterogeneous and frequently spread over the body, making their imaging difficult. With this aim, nuclear medicine imaging, using PET or SPECT with different tracers, has been proposed for decades, but there is currently no consensus on the most appropriate technique, even when only considering gastrointestinal NET. The case is presented of a 67year old woman with a well differentiated NET of the ileum with suspected recurrence, which was not detected by any imaging technique except 18F-FDOPA PET/CT. Subsequent follow up showed disease progression, which confirmed the true positivity of 18F-FDOPA. Using this case, we discuss and compare different radiotracers for the diagnosis of gastrointestinal NET, focusing on those embryologically originating from the mid-gut.
Collapse
Affiliation(s)
- N Testart Dardel
- Servicio de Medicina Nuclear, Hôpital Tenon AP-HP et Université P & Marie Curie, París, Francia; Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Granada, Granada, España.
| | - F Montravers
- Servicio de Medicina Nuclear, Hôpital Tenon AP-HP et Université P & Marie Curie, París, Francia
| | - E Triviño-Ibañez
- Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Granada, Granada, España
| | - M Gauthé
- Servicio de Medicina Nuclear, Hôpital Tenon AP-HP et Université P & Marie Curie, París, Francia
| | - S Houry
- Servicio de Cirugía, Hôpital Tenon AP-HP et Université P & Marie Curie, París, Francia
| | - J N Talbot
- Servicio de Medicina Nuclear, Hôpital Tenon AP-HP et Université P & Marie Curie, París, Francia
| |
Collapse
|
9
|
Talbot JN, Gligorov J, Nataf V, Montravers F, Huchet V, Michaud L, Ohnona J, Balogova S, Cussenot O, Daraï E, Lotz JP, Kerrou K. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone. Q J Nucl Med Mol Imaging 2015; 59:4-17. [PMID: 25693420] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Currently, the most frequent approach in the oncologic applications of positron emission tomography (PET) is detecting the hypermetabolic activity of the cancer tissue. A more specific approach, which may be complementary, is detecting the overexpression of receptors. In this review article, we aim to evaluate the results that are currently available for PET imaging of the sex hormone receptors in clinical oncology. The indication of PET and now PET/CT has been more disputed in breast carcinoma than in many other primary cancers (e.g., lung, head and neck, colorectal, lymphoma). 18F-fluorodeoxyglucose (FDG), the glucose analogue for PET imaging, has a limited sensitivity to detect the primary breast tumors in case of lobular or in situ forms or small sized tumors localised on systematic mammography, and to identify minimal node invasion in the axilla. Using 16α-[¹⁸F]fluoro-17β-estradiol (FES), a fluorinated estradiol analogue, PET is able to detect the over-expression of the oestrogen receptor (ER) in lesions, at a whole-body level. FES and FDG appear complementary for a better diagnostic performance in staging locally advanced breast cancer or restaging recurrent or metastatic breast cancer. Another potential indication is predicting the response to starting or resuming hormone therapy in patients with metastatic breast cancer, in relation with the ER status of all lesions revealed by FES PET. In two retrospective studies, FDG PET was also able to predict the response to hormone therapy, on basis of a metabolic flare, observed either after 7-10 days of treatment or during an estradiol challenge. A prospective comparison of those approaches is warranted. One study reported predicting response to neoadjuvant chemotherapy thanks to a low value of FES SUV(max) or FES/FDG SUV(max) ratio. The presence of ER in uterine tumors, including the benign ones, in ovarian cancers or even in meningiomas, may have therapeutic consequences and FES PET could have a clinical utility in those settings; only initial results are available. The indication of PET and PET/CT has been even more disputed in prostate carcinoma, due to the lack of significant FDG uptake in most cases, at least before the castration-resistant stage. Using FDHT, a fluorinated testosterone analogue, PET is able to detect the over-expression of the androgen receptor (AR) in lesions, at a whole-body level. At least partly due to the rather large number of alternative tracers that are in development or even routinely available in some countries, few FDHT studies have been published until now. From absorbed dose values previously published for FES by the team of University of Washington School of Medicine at Seattle, and for FDHT by the teams of Memorial Sloan-Kettering Cancer Center at New York and of Washington University at St. Louis, we applied the coefficients of ICRP publication 103 and calculated an effective dose per unit of injected activity of 0.023 mSv/MBq for FES and 0.018 mSv/MBq for FDHT. The radiation exposure is of the same order of magnitude as with FDG.
Collapse
Affiliation(s)
- J N Talbot
- Department of Nuclear Medicine, Hôpital Tenon AP‑HP et Université Pierre et Marie Curie, Paris, France -
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Prignon A, Nataf V, Provost C, Cagnolini A, Montravers F, Gruaz-Guyon A, Lantry LE, Talbot JN, Nunn AD. (68)Ga-AMBA and (18)F-FDG for preclinical PET imaging of breast cancer: effect of tamoxifen treatment on tracer uptake by tumor. Nucl Med Biol 2014; 42:92-8. [PMID: 25459112 DOI: 10.1016/j.nucmedbio.2014.10.003] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2014] [Revised: 09/22/2014] [Accepted: 10/01/2014] [Indexed: 02/02/2023]
Abstract
INTRODUCTION AMBA is a bombesin analogue that binds to GRPr. In a mouse model of estrogen-dependent human breast cancer, we tested whether (68)Ga-AMBA can be used for PET detection of GRPr-expressing tumors and could be more accurate than (18)F-FDG to monitor tumor response to hormone therapy. METHODS The radiolabeling of (68)Ga-AMBA was automated using a R&D Synchrom module. ZR75-1, a breast cancer cell line, was xenografted in nude mice. (68)Ga-AMBA tumor uptake was compared with that of (18)F-FDG before and after treatment with tamoxifen. RESULTS AMBA was (68)Ga-radiolabelled in 30min with 95.3% yield and purity≥98%. Prior to treatment, (68)Ga-AMBA was highly concentrated into tumors (tumor to non-tumor ratio=2.4 vs. 1.3 with (18)F-FDG). With tamoxifen treatment (n=6) (68)Ga-AMBA uptake plateaued after 1week and decreased after 2weeks, with a significant reduction compared to controls (n=4). In contrast the effect of tamoxifen treatment could not be appreciated using (18)F-FDG. CONCLUSIONS (68)Ga-AMBA appeared better than (18)F-FDG to visualize and monitor the response to hormone treatment in this breast cancer model.
Collapse
Affiliation(s)
- A Prignon
- Plateforme LIMP, UMS28 Phénotypage du petit animal, UPMC, Paris, France.
| | - V Nataf
- Plateforme LIMP, UMS28 Phénotypage du petit animal, UPMC, Paris, France; APHP, Hôpital Tenon, Médecine nucléaire, Paris, France
| | - C Provost
- Plateforme LIMP, UMS28 Phénotypage du petit animal, UPMC, Paris, France
| | | | - F Montravers
- Plateforme LIMP, UMS28 Phénotypage du petit animal, UPMC, Paris, France; APHP, Hôpital Tenon, Médecine nucléaire, Paris, France
| | | | | | - J N Talbot
- Plateforme LIMP, UMS28 Phénotypage du petit animal, UPMC, Paris, France; APHP, Hôpital Tenon, Médecine nucléaire, Paris, France
| | - A D Nunn
- Bracco Research USA, Princeton USA
| |
Collapse
|
11
|
Metivier D, Montravers F, Balogova S, Talbot JN. 18F-FDG PET/CT uptake due to poly-L-lactic acid facial injections. Nuklearmedizin 2013; 52:N66-N67. [PMID: 24337016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2013] [Accepted: 08/26/2013] [Indexed: 06/03/2023]
|
12
|
Balogova S, Michaud L, Vereb M, Decazes P, Huchet V, Kerrou K, Fartoux L, Montravers F, Rosmorduc O, Talbot JN. 18F-fluorocholine may be taken-up by brown adipose tissue. Nuklearmedizin 2013. [DOI: 10.1055/s-0038-1622732] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
13
|
Métivier D, Montravers F, Balogova S, Talbot JN. 18F-FDG PET/CT uptake due to poly-L-lactic acid facial injections. Nuklearmedizin 2013. [DOI: 10.1055/s-0038-1625227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
14
|
Balogova S, Michaud L, Vereb M, Decazes P, Huchet V, Kerrou K, Fartoux L, Montravers F, Rosmorduc O, Talbot JN. 18F-fluorocholine may be taken-up by brown adipose tissue. Nuklearmedizin 2013; 52:N3-N4. [PMID: 24395333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2012] [Accepted: 11/13/2012] [Indexed: 06/03/2023]
|
15
|
Bachmeyer C, Kerrou K, Chosidow O, Frances C, Montravers F. 18-F fluorodeoxyglucose positron emission tomography indicating unsuspected infections in two patients with dermatomyositis. Clin Exp Dermatol 2009; 34:e769-71. [DOI: 10.1111/j.1365-2230.2009.03496.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
16
|
Montravers F, Kerrou K, Huchet V, Pascal O, Talbot JN. TEP-TDM au FDG et lymphomes de Hodgkin de l’enfant. Arch Pediatr 2009; 16:669-71. [DOI: 10.1016/s0929-693x(09)74106-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
17
|
Montravers F, de Bazelaire C, Kerrou K, Farges C, Huchet V, Talbot JN, Frija J, de Kerviler K. PET-CT and oncology—an overview [in French). Imaging and PET-CT of adult and childhood lymphoma. Clin Imaging 2009. [DOI: 10.1016/j.clinimag.2008.10.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
18
|
Montravers F, de Bazelaire C, Kerrou K, Farges C, Huchet V, Talbot JN, Frija J, de Kerviler E. Imagerie radiologique et TEP scanner des lymphomes de l’adulte et de l’enfant. ACTA ACUST UNITED AC 2008; 89:371-84; quiz 385-6. [DOI: 10.1016/s0221-0363(08)89015-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
19
|
Sobhani I, Tiret E, Lebtahi R, Aparicio T, Itti E, Montravers F, Vaylet C, Rougier P, André T, Gornet JM, Cherqui D, Delbaldo C, Panis Y, Talbot JN, Meignan M, Le Guludec D. Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer. Br J Cancer 2008; 98:875-80. [PMID: 18301402 PMCID: PMC2266857 DOI: 10.1038/sj.bjc.6604263] [Citation(s) in RCA: 100] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
We assessed the potential benefits of including systematic 18fluorodeoxyglucose positron emission tomography (FDG-PET) for detecting tumour recurrence in a prospective randomised trial. Patients (N=130) who had undergone curative therapy were randomised to undergo either conventional (Con) or FDG-PET procedures during follow-up. The two groups were matched at baseline. Recurrence was confirmed histologically. ‘Intention-to-treat’ analysis revealed a recurrence in 46 patients (25 in the FDG-PET group, and 21 in the Con group; P=0.50), whereas per protocol analysis revealed a recurrence in 44 out of 125 patients (23 and 21, respectively; P=0.60). In another three cases, PET revealed unexpected tumours (one gastric GIST, two primary pulmonary cancers). Three false-positive cases of FDG-PET led to no beneficial procedures (two laparoscopies and one liver MRI that were normal). We failed to identify peritoneal carcinomatosis in two of the patients undergoing FDG-PET. The overall time in detecting a recurrence from the baseline was not significantly different in the two groups. However, recurrences were detected after a shorter time (12.1 vs 15.4 months; P=0.01) in the PET group, in which recurrences were also more frequently (10 vs two patients) cured by surgery (R0). Regular FDG-PET monitoring in the follow up of colorectal cancer patients may permit the earlier detection of recurrence, and influence therapy strategies.
Collapse
Affiliation(s)
- I Sobhani
- Université Paris 12 et Hôpital Henri Mondor, 51 Av du Mal de Lattre de Tassigny, Créteil 94100, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Sézeur A, Châtelet FP, Cywiner C, de Labriolle-Vaylet C, Chastang C, Billotey C, Malafosse M, Gallot D, Betton P, Montravers F, Carvajal-Gonzalez S, Askienazy S, Talbot JN, Rain JD, Milhaud G, Saumon G, Barbet J, Gruaz-Guyon A. Pathology underrates colon cancer extranodal and nodal metastases; ex vivo radioimmunodetection helps staging. Clin Cancer Res 2007; 13:5592s-5597s. [PMID: 17875794 DOI: 10.1158/1078-0432.ccr-07-1235] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE Colorectal carcinoma is frequently accompanied by small lymph nodes metastases that often escape pathologic examination. We evaluated whether ex vivo radioimmunodetection with the Affinity Enhancement System (AES) could improve detection of mesocolonic metastases. EXPERIMENTAL DESIGN A bivalent 111In-labeled hapten was injected (16 patients) 4 days after a bispecific antibody (anticarcinoembryonic antigen, antihapten). Surgery was done 1 to 3 days later, and radioactive uptake in the mesocolon was recorded. Extensive pathologic examination of the mesocolon (reference method) was done after fat dissolution. This method visualizes all lymph nodes but is not in routine use. RESULTS The reference method disclosed 705 nodes. There was no significant difference between the number of node metastases detected by AES or by the reference method (16 versus 17). Better detection would have been obtained by AES than by routine pathology (P<0.01). In addition 12 extranodal metastases were found in this study of which eight were detected by AES. The prognostic importance of such extranodal metastases has been underlined in the literature. Routine pathology combined with AES would have disclosed all node metastases and 86% of total metastases versus 35% by routine pathology alone. CONCLUSIONS Ex vivo radioimmunodetection could improve nodal and extranodal metastases detection in patients with colorectal cancer. Its value for improving pathologic analysis, together with the effect of these small metastases on prognosis, should be further evaluated. The benefit of adjuvant chemotherapy for patients upstaged with radioimmunodection should also be assessed because adjuvant chemotherapy improves the 5-year survival of stage III patients.
Collapse
Affiliation(s)
- A Sézeur
- Service de Chirurgie Digestive et Générale, Groupe Hospitalier Diaconesses-Croix Saint Simon, and Université Pierre et Marie Curie-Paris 6, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Clarençon F, Kerrou K, Gutman F, Chevallier D, Montravers F, Talbot JN. Asymmetric F-18 fluorocholine uptake of submaxillary glands revealing intraglandular lithiasis. Clin Nucl Med 2007; 32:165-7. [PMID: 17242581 DOI: 10.1097/01.rlu.0000252183.30491.55] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- F Clarençon
- Service de Médecine Nucléaire, Hopital Tenon, Paris, France.
| | | | | | | | | | | |
Collapse
|
22
|
Aflalo-Hazan V, Gutman F, Raileanu I, Frétault J, Kerrou K, Grahek D, Montravers F, Talbot JN. [18F-FDG PET and bone scintigraphy to search for bone metastasis of lung cancer]. Rev Pneumol Clin 2006; 62:164-9. [PMID: 16840993 DOI: 10.1016/s0761-8417(06)75432-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/10/2023]
Abstract
Initial staging of lung cancer is essential to determine the appropriate therapeutic strategy. 18F-FDG PET is currently considered to be the gold standard. 99mTc bisphonate bone scintigraphy has long been indicated to search for bone metastases but it is not know whether this exploration adds further information after an 18F-FDG PET scan. In order to answer this question, two observers unaware of the clinical situation reread PET scans and bone scintigraphies and results compared with other imaging findings. Between February 2001 and March 2004, 39 patients (13F, 26M, 62 +/- 11 yr) underwent 18FFDG PET and bone scintigraphy (mean interval 17 +/- 17 d). When the two explorations agreed for the diagnosis of bone extension, we considered that bone scintigraphy added nothing. When the two explorations were in disagreement, the other imaging examinations, the clinical features and laboratory results during the five-month minimal follow-up were used to establish the reference diagnosis. 18F-FDG PET and bone scintigraphy were in agreement in 29 patients (74%) with positive results in 12 (31%) and negative results in 17 (43%). The two explorations were in disagreement in 10 patients (26%). Among the five disagreement cases with positive bone scintigraphy and no bone anomaly on the 18F-FDG PET, the anomalies were benign and explained by clinical features (3 patients) or were not confirmed by the clinical course and laboratory results (2 patients). Among the 5 cases with a bone anomaly on the 18F FDG PET, no metastasis could be identified during clinical follow-up. Bone scintigraphy does not enable identification of any bone metastases which were not recognized on the PET scan and therefore should not be performed systematically. Using a computed tomography scan with the 18F-FDG PET could further limit the contribution of bone scintigraphy by providing more precision concerning foci identified on the PET scan.
Collapse
Affiliation(s)
- V Aflalo-Hazan
- Service de Médecine Nucléaire, Hôpital Tenon, AP-HP, 4, rue de la Chine, 75970 Paris Cedex 20
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Affiliation(s)
- V Aflalo-Hazan
- Department of Nuclear Medicine, Höpital Tenon, Paris, France
| | | | | | | | | | | |
Collapse
|
24
|
Deniaud-Alexandre E, Touboul E, Lerouge D, Grahek D, Foulquier JN, Petegnief Y, Grès B, El Balaa H, Keraudy K, Kerrou K, Montravers F, Milleron B, Lebeau B, Talbot JN. Tomographie par émission de positons et détection en coïncidence (TEDC) et recalage d'images de simulation virtuelle par tomodensitométrie. Impact sur la planification de la radiothérapie conformationnelle des cancers bronchiques non à petites cellules. Cancer Radiother 2005; 9:304-15. [PMID: 16087377 DOI: 10.1016/j.canrad.2005.07.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2005] [Revised: 06/22/2005] [Accepted: 07/01/2005] [Indexed: 10/25/2022]
Abstract
UNLABELLED To report a retrospective study concerning the impact of fused 18F-fluorodeoxy-D-glucose (FDG)-hybrid positron emission tomography (PET) and computed tomography (CT) images on three-dimensional conformal radiation therapy (3D-CRT) planning for patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS One hundred and one patients consecutively treated for stages I-III NSCLC were studied. Each patient underwent CT and FDG-hybrid PET for simulation treatment in the same radiation treatment position. Images were coregistered using five fiducial markers. Target volume delineation was initially performed on the CT images and the corresponding FDG-PET data were subsequently used as an overlay to the CT data to define target volume. RESULTS FDG-PET identified previously undetected distant metastatic disease in 8 patients making them ineligible for curative CRT (one patient presented some positive uptakes corresponding to concomitant pulmonary tuberculosis). Another patient was ineligible for curative treatment because fused CT/PET images demonstrated excessively extensive intrathoracic disease. The gross tumor volume (GTV) was decreased by CT/PET image fusion in 21 patients (23%) and was increased in 24 patients (26%). The GTV reduction was > or = 25% in 7 patients because CT/PET image fusion reduced pulmonary GTV in 6 patients (3 patients with atelectasis) and mediastinal nodal GTV in 1 patient. The GTV increase was > or = 25% in 14 patients due to an increase of the pulmonary GTV in 11 patients (4 patients with atelectasis) and detection of occult mediastinal lymph node involvement in 3 patients. Among 81 patients receiving a total dose > or = 60 Gy at ICRU point, after CT/PET image fusion, the percentage of total lung volume receiving more than 20 Gy (VL20) increased in 15 cases and decreased in 22 cases. The percentage of total heart volume receiving more than 36 Gy increased in 8 patients and decreased in 14 patients. The spinal cord volume receiving at least 45 Gy (2 patients) decreased. After multivariate analysis, one single independent factor made significant effect of FDG/PET on the modification of the size of the GTV: tumor with atelectasis (P = 0.0001). Conclusion. - Our study confirms that integrated hybrid PET/CT in the treatment position and coregistered images have an impact on treatment planning and management of patients with NSCLC. FDG images using dedicated PET scanners with modern image fusion techniques and respiration-gated acquisition protocols could improve CT/PET image coregistration. However, prospective studies with histological correlation are necessary and the impact on treatment outcome remains to be demonstrated.
Collapse
Affiliation(s)
- E Deniaud-Alexandre
- Service d'oncologie-radiothérapie, hôpital Tenon, AP-HP, 4, rue de la Chine, 75970 Paris cedex 20, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Talbot JN, Kerrou K, Missoum F, Grahek D, Aide N, Lumbroso J, Montravers F. 6-[F-18]Fluoro-l-DOPA Positron Emission Tomography in the Imaging of Merkel Cell Carcinoma: Preliminary Report of Three Cases with 2-Deoxy-2-[F-18]Fluoro-d-Glucose Positron Emission Tomography or Pentetreotide-(111In) SPECT Data. Mol Imaging Biol 2005; 7:257-61. [PMID: 16082495 DOI: 10.1007/s11307-005-0006-3] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
PURPOSE Merkel cell carcinoma (MCC) is an uncommon and aggressive cutaneous neoplasm of neuroendocrine origin. Somatostatin receptor scintigraphy (SRS) and positron emission tomography (PET) using 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) have been proposed to stage MCC and to detect early recurrences. As 6-[F-18]fluoro-L-DOPA (FDOPA) is taken up by other neuroendocrine tumors, we speculated that FDOPA-PET could image MCC. PROCEDURE FDOPA-PET was performed together with FDG-PET (three patients) and SRS (two patients) in different clinical settings: localization of the primary tumor, staging, and suspicion of recurrence. RESULTS Uptake of FDOPA-(18F) by MCC was observed in the two true-positive cases, with an agreement between the results of FDOPA-PET, FDG-PET, and SRS; however, the contrast was lower on FDOPA-PET than on FDG-PET images. In the last patient suspected of recurrence repeatedly on SRS and with inconclusive FDG-PET, FDOPA-PET was negative, and a 12-month follow-up demonstrated a true-negative result. CONCLUSION MCC takes up FDOPA-(18F). The potential role of FDOPA-PET in its management warrants clarification.
Collapse
Affiliation(s)
- Jean-Noël Talbot
- Médecine nucléaire et Centre TEP AP-HP, Hopital Tenon, Paris, France.
| | | | | | | | | | | | | |
Collapse
|
26
|
Moureau-Zabotto L, Touboul E, Lerouge D, Deniaud-Alexandre E, Grahek D, Foulquier JN, Petenief Y, Grès B, El Balaa H, Kerrou K, Montravers F, Keraudy K, Tiret E, Gendre JP, Grange JD, Hourry S, Talbot JN. Tomographie par émission de positons et fusion d'images de simulation virtuelle par tomodensitométrie. Impact sur la planification de la radiothérapie conformationnelle des cancers de l'œsophage. Cancer Radiother 2005; 9:152-60. [PMID: 16023043 DOI: 10.1016/j.canrad.2005.04.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2005] [Revised: 03/18/2005] [Accepted: 04/01/2005] [Indexed: 11/25/2022]
Abstract
PURPOSE To study the impact of fused (18)F-fluoro-deoxy-D-glucose (FDG)-hybrid positron emission tomography (PET) and computed tomography (CT) images on conformal radiation therapy (CRT) planning for patients with esophageal carcinoma. PATIENTS AND METHODS Thirty-four patients with esophageal carcinoma were referred for concomitant radiotherapy and chemotherapy with radical intent. Each patient underwent CT and FDG-hybrid PET for simulation treatment in the same radiation treatment position. PET-images were coregistered using five fiducial markers. Target delineation was initially performed on CT images and the corresponding PET data were subsequently used as an overlay to CT data to define the target volume. RESULTS FDG-PET identified previously undetected distant metastatic disease in 2 patients, making them ineligible for curative CRT. The Gross Tumor Volume (GTV) was decreased by CT and FDG image fusion in 12 patients (35%) and was increased in 7 patients (20.5%). The GTV reduction was >or=25% in 4 patients due to reduction of the length of the esophageal tumor. The GTV increase was >or=25% with FDG-PET in 2 patients due to the detection of occult mediastinal lymph node involvement in one patient and an increased length of the esophageal tumor in the other patient. Modifications of the GTV affected the planning treatment volume (PTV) in 18 patients. Modifications of delineation of GTV and displacement of the isocenter of PTV by FDG-PET also affected the percentage of total lung volume receiving more than 20 Gy (VL20) in 25 patients (74%), with a dose reduction in 12 patients and a dose increase in 13 patients. CONCLUSION In our study, CT and FDG-PET image fusion appeared to have an impact on treatment planning and management of patients with esophageal carcinoma related to modifications of GTV. The impact on treatment outcome remains to be demonstrated.
Collapse
Affiliation(s)
- L Moureau-Zabotto
- Service d'oncologie-radiothérapie, hôpital Tenon AP-HP, 4, rue de la Chine, 75020 Paris et CancerEst, université Paris-VI, GHU Est, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Girard T, Nochy D, Montravers F, Der Sahakian G, Fior R, Galanaud P, Boué F. Intra-vascular large B-cell lymphoma revealed by a nephrotic syndrome: a one year remission induced by a high frequency CHOP and rituximab. Leuk Lymphoma 2004; 45:1703-5. [PMID: 15370230 DOI: 10.1080/10428190410001683822] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Intra-vascular lymphoma is usually reported as a rare and fatal disorder. We describe here the first case of an intra-vascular lymphoma revealed by a nephrotic syndrome for which a durable remission has been obtained by 8 cycles of bi-mensual CHOP and Rituximab therapy. In this report, 18 fluorodesoxyglucose tomoscintigraphy is discussed as a tool for intra-vascular lymphoma extension and follow-up.
Collapse
MESH Headings
- Aged
- Antibodies, Monoclonal/therapeutic use
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Agents/therapeutic use
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Cyclophosphamide/therapeutic use
- Doxorubicin/therapeutic use
- Female
- Humans
- Lymphoma, B-Cell/drug therapy
- Lymphoma, B-Cell/pathology
- Lymphoma, Large B-Cell, Diffuse/drug therapy
- Lymphoma, Large B-Cell, Diffuse/pathology
- Nephrotic Syndrome/pathology
- Prednisone/therapeutic use
- Remission Induction
- Rituximab
- Tomography, Emission-Computed, Single-Photon
- Vascular Neoplasms/drug therapy
- Vascular Neoplasms/pathology
- Vincristine/therapeutic use
Collapse
Affiliation(s)
- T Girard
- Service de Medecine Interne, Hôpital Antoine Béclère, Faculté de Médecine Paris-Sud, Paris, France.
| | | | | | | | | | | | | |
Collapse
|
28
|
Zacharias T, Barrier A, Montravers F, Houry S, Lacaine F, Huguier M. Cardio-esophageal cancer. Is 18Fluorodeoxyglucose positron emission tomography worthwhile? Hepatogastroenterology 2004; 51:741-3. [PMID: 15143905] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Abstract
BACKGROUND/AIMS 18Fluorodeoxyglucose positron emission tomography has been proposed for the preoperative staging of carcinomas of the esophagus and gastric cardia. The aim of this study was to assess its diagnostic value and its influence on therapeutical decisions. METHODOLOGY Twenty-eight patients with a cancer of the esophagus or gastric cardia underwent a 18Fluorodeoxyglucose positron emission tomography on a gamma camera with coincidence detection electronics, in addition to our standard preoperative procedures (barium swallow, liver ultrasonography, chest X-ray). Four types of lesions were searched for: primary tumor, abdominal and mediastinal lymph nodes, and distant metastases. Results of 18Fluorodeoxyglucose positron emission tomography were compared to pathological findings. RESULTS Sensitivity for the primary tumor was 86%. Sensitivity for mediastinal and abdominal lymph nodes was 75 and 54%, respectively, whereas specificity was 100%. Distant metastases were detected in 4 patients: liver metastasis in 2 patients and bone metastasis in 2 patients. Results of 18Fluorodeoxyglucose positron emission tomography influenced therapeutical decisions for 2 patients. CONCLUSIONS 18Fluorodeoxyglucose positron emission tomography seems to be worthwhile in the preoperative staging of carcinomas of the esophagus and gastric cardia, mainly because it may detect distant metastases.
Collapse
|
29
|
Plaza P, Montravers F, Aide N, Carrera D, Kerrou K, Ferran N, Grahek D, Talbot JN. Valoración de un tumor neuroendocrino mediante gammagrafía con 111In-pentetreótido y PET con 18F-FDOPA y 18F-FDG. ACTA ACUST UNITED AC 2004; 23:421-4. [PMID: 15625060 DOI: 10.1016/s0212-6982(04)72332-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
We present the case of a 67 year old patient diagnosed of a neuroendocrine carcinoid tumour of the small intestine. The tumour and subsequent metastases were resected previously by surgery, but a new recurrence was suspected. CT showed left adrenal enlargement. 18F-FDG PET was normal and 111In pentetreotide scintigraphy showed liver and left diaphragmatic uptake. 18F-FDOPA PET showed uptake foci in liver and left diaphragm and also in left adrenal gland, retro urinary bladder area and multiple foci in abdominopelvic region, suggesting a peritoneal carcinomatosis. 18F-FDOPA PET was the first imaging modality to assess the extensiveness of the disease that was confirmed six month later by CT. Neuroendocrine tumors are a heterogeneous group of neoplasia. They are studied by conventional radiologic and functional techniques of nuclear medicine. This case illustrates the need to use the different techniques and tracers according to the characteristics of the tumor to be studied to thus improve the diagnostic and prognostic performance.
Collapse
Affiliation(s)
- P Plaza
- Servicio de Medicina Nuclear, Hospital Universitario de Bellvitge, Barcelona.
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Balogova S, Grahek D, Kerrou K, Montravers F, Younsi N, Aide N, Jacob T, Talbot JN. [[18F]-FDG imaging in apparently isolated pleural lesions]. Rev Pneumol Clin 2003; 59:275-288. [PMID: 14707923] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
UNLABELLED While a great deal of work has been performed concerning the impact of [18F]-FDG imaging in isolated lung lesion(s), there are still very few data about its role in case of isolated pleural lesions. The aim of this preliminary study was to shed some light on the utility of [18F]-FDG imaging, using PET or CDET detection, in this context. PATIENTS AND METHOD Sixteen patients referred for apparently isolated pleural lesions were included in this study, since their 22 [18F]-FDG examinations were evaluable on bases of histology (9 cases), rapid disease progression (4 cases) or a follow-up period of more than 6 months (9 cases). Twelve [18F]-FDG examinations were performed with a dedicated PET machine (C-PET, Adac) and ten with a coincidence detection gamma camera (Irix, Picker). The precise clinical settings were the following: characterization of pleural masses or search for the unknown primary tumor in case of adenocarcinoma (6 cases), staging of a mesothelioma (5 cases), suspicion of recurrence and/or residual lesions (11 cases). RESULTS The malignant pleural lesions took up [18F]-FDG in all cases. There was one false positive result due to an inflammatory lesion. False negative results for the detection of lymph node invasion occurred in three patients and were in relation with their infracentimetric size and the difficulty to distinguish on [18F]-FDG images mediastinal lymph nodes from widespread pleural and pulmonary extension of cancer. A change in patient management resulted from the [18F]-FDG examination in 4 patients (25%) and the course confirmed that the change was correct. Unknown lesions or active lesions wrongly considered residual that could have modified the management were discovered in 3 other patients. CONCLUSIONS This study highlights the fact that [18F]-FDG imaging has an impact on the management of patients with solitary pleural lesions and can detect recurrences, in some cases even more accurately than invasive procedures with histology. In our limited experience, the lack of anatomical details of the PET images is a major drawback in this setting and we are convinced that PET-CT will substantially enhance the impact of [18F]-FDG imaging.
Collapse
Affiliation(s)
- S Balogova
- Service de Médecine Nucléaire et Centre TEP AP-HP, Hôpital Tenon et Université Pierre-et-Marie-Curie, 4, rue de la Chine, 75020 Paris
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Bourguet P, Blanc-Vincent MP, Boneu A, Bosquet L, Chauffert B, Corone C, Courbon F, Devillers A, Foehrenbach H, Lumbroso JD, Mazselin P, Montravers F, Moretti JL, Talbot JN. Summary of the Standards, Options and Recommendations for the use of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose (FDP-PET scanning) in oncology (2002). Br J Cancer 2003; 89 Suppl 1:S84-91. [PMID: 12915907 PMCID: PMC2753008 DOI: 10.1038/sj.bjc.6601088] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
32
|
Des Guetz G, Montravers F, Tabah I, Grahek D, Talbot JN, Bouillot JL, Pujade-Lauraine E. Isolated metastatic adrenal involvement with colon cancer and FDG coincidence detection imaging. Clin Nucl Med 2003; 28:238. [PMID: 12592139 DOI: 10.1097/01.rlu.0000053537.01664.bf] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- G Des Guetz
- Departments of Hematology and Medical Oncology, Hôspital Tenon, Paris, France.
| | | | | | | | | | | | | |
Collapse
|
33
|
Kerrou K, Camatte S, Lelievre L, Metzger U, Lefrere-Belda MA, Grahek D, Montravers F, Talbot JN, Lecuru F. PREOPERATIVE CHARACTERISATION AND STAGING OF OVARIAN TUMOURS BY 18-FDG: A PROSPECTIVE SERIES. Int J Gynecol Cancer 2003. [DOI: 10.1136/ijgc-00009577-200303001-00070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
34
|
Talbot JN, Montravers F, MacNamara D, Grahek D, Kerrou K, Younsi N. 21. Clinical utility and impact on management of the 18F-FDG examination in staging and follow-up of childhood lymphoma. Nucl Med Commun 2002. [DOI: 10.1097/00006231-200212000-00032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
35
|
Montravers F, Kerrou K, Grahek D, Zerbib E, Mabille L, Younsi N, Petegnief Y, De Beco V, Colombet-Lamau C, Talbot JN. [Value of [18F]-fluorodeoxyglucose (FDG) positron emission tomography in digestive cancerology]. Presse Med 2002; 31:1560-8. [PMID: 12422485] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/27/2023] Open
Abstract
COLORECTAL CANCERS: FDG-PET is a very effective tool in the follow-up of colorectal cancer for the early detection of recurrences, the search for other localisations in case of resectable lesions and for the evaluation of therapies. For the other digestive cancers, the data in the literature are less abundant and they do not yet have Marketing Authorization in France. OESOPHAGEAL CANCER: FDG-PET appears very promising for staging and detection of recurrences of oesophageal carcinomas. Pancreatic cancer Although the indication is difficult, FDG-PET appears superior to morphological techniques for the characterization and the locoregional staging of pancreatic tumours. BILARY AND GASTRIC CARCINOMAS: FDG-PET is promising but its role has to be confirmed in larger series for the detection of biliary and gastric carcinomas. OTHER DIGESTIVE TUMOURS: In cases of hepatocarcinoma, FDG-PET appears efficient only in cases of undifferentiated tumours, and in cases of malignant neuroendocrine digestive tumours, is useful in combination with somatostatin receptor imaging.
Collapse
Affiliation(s)
- F Montravers
- Service de médecine nucléaire et centre TEP AP-HP, Hôpital Tenon, 4 rue de la Chine 75020 Paris.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Montravers F, McNamara D, Landman-Parker J, Grahek D, Kerrou K, Younsi N, Wioland M, Leverger G, Talbot JN. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management. Eur J Nucl Med Mol Imaging 2002; 29:1155-65. [PMID: 12192560 DOI: 10.1007/s00259-002-0861-y] [Citation(s) in RCA: 117] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (FDG) is a very useful technique for the imaging of lymphomas in the adult population. It provides unique information about the behaviour of malignant cells and contributes to more accurate staging of the illness and better assessment of response to therapy. The purpose of this study was to evaluate the usefulness of FDG PET in childhood lymphoma compared with conventional imaging methods (CIMs) and clinical data. Between July 1998 and August 2001, 42 FDG PET examinations were performed using a dedicated PET system (27 examinations) or a hybrid coincidence PET system (15 examinations) for initial tumour staging ( n=7), restaging ( n=5) or assessment of response to therapy or residual masses ( n=30) in 27 children with Hodgkin's disease (HD) ( n=20) or non-Hodgkin's lymphoma (NHL) ( n=7). FDG PET results were compared with CIM findings and clinical data. Since 2000, a standardised questionnaire for evaluation of the clinical impact of FDG PET on both staging and therapy has been sent to the 16 referring physicians and 13 have replied. In all children, FDG PET was performed without any side-effects. FDG PET was found to be very sensitive (Se=12/12) for staging and restaging of the illness, showing more lesions than CIMs, with a 50% patient upstaging rate (6/12). It was very accurate for monitoring response to therapy and for characterisation of residual masses. False-positive results were observed in two NHL patients with thymic uptake and one false-negative result was obtained in a patient whose NHL relapsed 1 month after a negative FDG PET. The questionnaire emphasised the impact of FDG PET on clinical management, which was modified on the basis of the FDG PET results in 23% of patients. As previously demonstrated in the adult population, FDG PET appeared to be a very sensitive imaging technique for staging and restaging of lymphoma in children and was very useful for monitoring the response to therapy.
Collapse
Affiliation(s)
- F Montravers
- Department of Nuclear Medicine and PET Centre, Hôpital Tenon, 4 rue de la Chine, 75020 Paris, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Talbot JN, Haioun C, Rain JD, Meignan M, Wioland M, Misset JL, Grahek D, Kerrou K, Montravers F. [18F]-FDG positron imaging in clinical management of lymphoma patients. Crit Rev Oncol Hematol 2001; 38:193-221. [PMID: 11369254 DOI: 10.1016/s1040-8428(01)00127-5] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
[18F]-FDG is a glucose analogue labelled with a short-lived positron emitter. During the past decade, it has been proposed to detect in vivo lymphoma lesions with PET, a new non-invasive imaging modality. We aimed at reviewing the current experience with FDG in several clinical settings of lymphoma. Due to the lack of specificity of FDG for lymphoma, histology remains compulsory to establish the diagnosis. Nevertheless, in the case of AIDS, FDG imaging has been proposed to differentiate lymphoma and opportunistic infections in brain lesions. To explore lymphoma extension, FDG-PET highlights more lesions than CT or the clinical examination and results in upstaging 13% of cases. It could also be used for selecting a site for biopsy when the location considered first clinically is difficult to access. Staging lymphoma with FDG-PET also provides baseline images for subsequent evaluation of therapy, which is one of the most promising indications: a negative scan predicts response to therapy and subsequent remission with a predictive value of 89%, and a positive scan either reflects resistance or predicts relapse with a predictive value of 83%. The current achievement of FDG imaging is the early detection of recurrence or of viable tissue in residual masses that remain several months after treatment. Both its sensitivity (84%) and its specificity (95%) overwhelm the values of conventional imaging, mainly CT and gallium-67 scintigraphy. When PET, as a new clinical imaging modality, is not yet widely demanded by clinicians and/or the number of FDG examinations is less than 500 per year, a 'hybrid' gamma-camera or CDET can be an alternative to dedicated PET. For 3 years, we have been using FDG-CDET in the 2D mode without attenuation correction, and obtained the following accuracy in a total of 40 examinations that could be evaluated: 85% for assessment of chemotherapy and 92% to detect recurrences and evaluate residual masses. Our preliminary results also stress the interest in FDG examination in childhood lymphoma, with the same indications as in adults.
Collapse
Affiliation(s)
- J N Talbot
- Lymphoma working party of the Assistance-Publique Hôpitaux de Paris (AP-HP) PET centre, Paris, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Grahek D, Montravers F, Mayaud C, Regnard JF, Kerrou K, Younsi N, Talbot JN. [Positron emission tomography (PET) with [18F]-FDG in bronchopulmonary cancer and its impact on medical decision at the time of diagnosis, staging, or recurrence evaluation]. Rev Pneumol Clin 2001; 57:393-403. [PMID: 11924148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
Clinical usefulness of [18F]-FDG imaging, performed by means of a dedicated or a "hybrid" PET machine, has been recognised in France since November 1998. Among the clinical indications, three major clinical settings of lung cancer have been included: characterisation, staging and detection of recurrences. After a brief presentation of the PET scintigraphic imaging modality, authors report on the experience of the nuclear medicine team of Hôspital Tenon and summarise the results in literature. For tumour characterisation, a recent meta-analysis obtained a 96% sensitivity, a 73% specificity, a 91% positive predictive value and a 90% negative predictive value, the performances being better for lesions greater than 1 cm. For staging, an increase greater than 15% both in sensitivity and specificity has been observed with dedicated or "hybrid" PET versus CT for N staging. Detection of distant metastases was also more accurate using [18F]-FDG. A similar increase was observed in the detection of recurrence, in accordance with our study; some authors described even better results. A better anatomical delineation of the lesions detected with FDG can be achieved by means of image fusion with CT; this technique is likely to develop as a routine tool in the near future. Finally, FDG imaging led to modification of patient's management in 37% of the cases according to a recent meta-analysis versus 53% of the cases in our retrospective survey concerning the first year of installation of a dedicated PET machine. This rate was equal with dedicated PET and with CDET. In 46% of the cases an inter-modality change occurred, and in 7% an intra-modality change consisting mainly in adaptation of the surgical procedure. As soon as the FDG examination became available, its clinical impact, in the French medical context, appeared to reach the highest values that were published internationally.
Collapse
Affiliation(s)
- D Grahek
- Service de Médecine Nucléaire, Hôpital Tenon (AP-HP), 4 rue de la Chine, 75020 Paris
| | | | | | | | | | | | | |
Collapse
|
39
|
Talbot JN, Grahek D, Kerrou K, Younsi N, de Beco V, Colombet-Lamau C, Petegnief Y, Cailleux N, Montravers F. [(18F)-fluoro-2-deoxyglucose PET in imaging of gynecologic cancers]. Gynecol Obstet Fertil 2001; 29:775-98. [PMID: 11770272 DOI: 10.1016/s1297-9589(01)00197-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Although gynaecological cancers are not currently part of the clinical indications in the French registration for [18F]-fluoro-2-deoxyglucose (FDG), various studies indicate in this context a potential clinical benefit of imaging with this radiopharmaceutical and PET, a new imaging modality that can be performed either with a dedicated machine or with a "hybrid" gamma-camera (CDET). The potential indications of FDG-PET in mammary, ovarian or cervical cancers are reviewed according to the diagnostic phase: screening, tumour characterisation, staging, therapeutic follow-up and search for recurrence. By pooling the published results, the accuracy of FDG-PET could be estimated with a reasonable precision in various clinical settings: characterisation of a breast tumour (598/696 = 86%), lymph node invasion in breast cancer (525/602 = 87%), recurrence of breast cancer (114/127 = 90%), characterisation of adnexal masses (130/176 = 78%), recurrence of ovarian cancer (152/172 = 88%), lymph node invasion in cervical cancer (98/103 = 95%). Authors also present original data concerning their experience of recurrence detection with CDET in breast or ovarian cancers. In 44 patients suspicious of recurrence of breast cancer, FDG-CDET sensitivity was 94%, specificity 82% and accuracy 91%; in 18 patients suspicious of recurrence of ovarian cancer, specificity, sensitivity and accuracy were 100%. The impact of dedicated PET and CDET examinations performed by our team during year 2000, led, according to 63 forms returned to us, to a modification of stage in 48% of breast cancers, 36% of ovarian cancers, 43% of cervical cancers and above all induced a modification in patients' management in respectively 69%, 64% and 60% of cases, more than the average rate in cancer patients which was 50%. No significant difference was observed between clinical impact of dedicated PET and CDET examinations.
Collapse
Affiliation(s)
- J N Talbot
- Service de médecine nucléaire, hôpital Tenon, AP-HP, Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Kerrou K, Montravers F, Grahek D, Younsi N, Perniceni T, Godeberge P, Canuel C, De Gramont A, Talbot JN. [18F]-FDG uptake in soft tissue dermatome prior to herpes zoster eruption: an unusual pitfall. Ann Nucl Med 2001; 15:455-8. [PMID: 11758954 DOI: 10.1007/bf02988353] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Authors report on a case of [18F]-fluorodeoxyglucose ([18F]-FDG) uptake in the soft tissue of a patient referred for [18F]-FDG coincidence detection emission tomography (CDET) in a search for recurrence of colorectal cancer. A herpes zoster eruption occurred in the same site within two days, but was spontaneously resolved. To the best of our knowledge this is the first description of a false positive [18F]-FDG result in relation to a viral infection of soft tissue. It shows that interpretation of subcutaneous foci has to be cautious in patients with or without a past history of herpes zoster even in pain-free areas and prior to skin eruption.
Collapse
Affiliation(s)
- K Kerrou
- Service de médecine nucléaire, Hôpital Tenon, Paris.
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Giraud P, Grahek D, Montravers F, Carette MF, Deniaud-Alexandre E, Julia F, Rosenwald JC, Cosset JM, Talbot JN, Housset M, Touboul E. CT and (18)F-deoxyglucose (FDG) image fusion for optimization of conformal radiotherapy of lung cancers. Int J Radiat Oncol Biol Phys 2001; 49:1249-57. [PMID: 11286831 DOI: 10.1016/s0360-3016(00)01579-0] [Citation(s) in RCA: 112] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
PURPOSE To validate a computed tomography (CT) and (18)F-deoxyglucose (FDG) image fusion procedure and to evaluate its usefulness to facilitate target definition and treatment planning in three-dimensional conformal radiation therapy (3D-CRT) for non-small-cell lung cancer. METHODS AND MATERIALS Twelve patients were assessed by CT and FDG-coincidence mode dual-head gamma camera (CDET) before radiotherapy. The patients were placed in a similar position during CT and FDG-CDET. Matching was achieved by minimizing the cost function by 3D translation and rotation between four landmarks drawn on the patient's skin. Virtual simulation was performed from image fusion and estimated dose-volume histograms (DVH) were calculated. RESULTS Quantitative analysis indicated that the matching error was < 5 mm. Fusion of anatomic and metabolic data corrected staging of lymph nodes (N) for 4 patients and staging of metastases for 1 patient. In these 5 patients, DVH revealed that the lung volume irradiated at 20 Gy (Vl(20)) was decreased by an average of 22.8%, and tumor volume irradiated at the 95% isodose (V(95)) was increased by 22% and 8% for 2 patients, respectively, and was decreased by an average of 59% for 3 patients after fusion. No difference in terms of Vl(20) and V(95) was observed for the other 7 patients. CONCLUSION We have validated CT and FDG-CDET lung image fusion to facilitate determination of lung cancer volumes, which improved the accuracy of 3D-CRT.
Collapse
Affiliation(s)
- P Giraud
- Department of Oncology-Radiotherapy, Hôpital Tenon, Paris, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Montravers F, Grahek D, Kerrou K, De Beco V, Younsi N, Talbot JN. [[18F]-fluorodeoxyglucose scintigraphy in digestive cancer]. Gastroenterol Clin Biol 2001; 25:B191-6. [PMID: 11449161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Affiliation(s)
- F Montravers
- Médecine Nucléaire, Hôpital Tenon, 4, rue de la Chine, 75020 Paris
| | | | | | | | | | | |
Collapse
|
43
|
Périé S, Talbot JN, Monceaux G, Grahek D, Kerrou K, Montravers F, St Guily JL. Use of a coincidence gamma camera to detect primary tumor with 18fluoro-2-deoxy-glucose in cervical lymph node metastases from an unknown origin. Ann Otol Rhinol Laryngol 2000; 109:755-60. [PMID: 10961809 DOI: 10.1177/000348940010900810] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
This study was performed to evaluate the ability of a dual-head gamma camera with 18fluoro-2-deoxy-glucose coincidence detection emission tomography (FDG-CDET) to detect primary tumors in patients with cervical lymph node metastases of head and neck squamous cell carcinoma from an unknown origin. From 60 patients with untreated head and neck squamous cell carcinoma, we selected 4 in whom no evidence of the primary's origin was found by the conventional methods used for the evaluation of head and neck tumors. In addition to the panendoscopy, chest radiography, a computed tomography (CT) scan, and FDG-CDET were performed. Both FDG-CDET and the CT scan located cervical lymph node metastases. In addition, FDG-CDET located the primary tumor in 3 of the 4 patients, and the tumors were confirmed with histopathologic findings. In contrast, the CT scan detected the primary tumor in none of them. FDG tomography performed on a coincidence gamma camera appears to be a successful new tool in detecting occult primary tumors in head and neck carcinoma, and is useful in guiding endoscopic biopsies. It has, further, the important potential ability to detect distant metastases on whole body images.
Collapse
Affiliation(s)
- S Périé
- Service d'Oto-Rhino-Laryngologie et Chirurgie de la Face et du Cou, Faculté de Médecine Saint Antoine, Université Paris VI, Hôpital Tenon, France
| | | | | | | | | | | | | |
Collapse
|
44
|
Montravers F, Grahek D, Kerrou K, Younsi N, Barrier A, Houry S, Lacaine F, Huguier M, Talbot JN. 14. FDG CDET (2D Dual-Head Coincidence Gamma Camera) in the Primary Staging of Oesophageal Cancer. Histopathological Correlation. Clin Positron Imaging 2000; 3:168. [PMID: 11150771 DOI: 10.1016/s1095-0397(00)00080-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Purpose: The aim of this study was to evaluate the role of FDG-CDET for the detection of primary oesophageal tumour, lymph node involvement and distant extension before surgery.Methods and patients: In patients fasting for 6h or more, 150-250 MBq of 18F-FDG were injected i.v. and 2D imaging (whole-body scan and at least a tomoscintigram) was started 45 min. later, using a PICKER gamma camera. We studied 14 patients (pts). All of them were operated on (mean time between FDG and surgery: 5.4 +/- 3.8 days) and staging results were correlated with post surgical histology.Results: The primary lesion took up FDG in all cases but one (FN in a 5 mm lesion). The primary NM staging of these 14 pts was negative with FDG-CDET in 7 cases (4 TN and 3 FN corresponding to an invasion of satellite lymph nodes in 2 cases and to a metastatic infracentimetric subdiaphragmatic lymph node in one case) and positive in 7 cases (7 TP corresponding to 10 foci), revealing in 4 cases a sub-diaphragmatic lymph node extension unknown prior to FDG-CDET. One pt referred for characterisation of an oesophageal lesion (failure of multiple biopsies) had an intense focus of FDG uptake in this area (TP confirmed by surgery). The overall sensitivity was 13/14 = 93% on a per patient basis and 21/25 = 84% on a per lesion basis. Specificity on a per lesion basis was 5/5 = 100%.Conclusion: These first results, obtained in an indication of FDG not frequently evaluated even with dedicated PET systems, seem very promising, the oesophageal neoplastic lesions appearing to take up FDG with a high intensity.
Collapse
Affiliation(s)
- F Montravers
- Department of nuclear medicine, hôpital Tenon, AP-HP, Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Montravers F, Grahek D, Kerrou K, Younsi N, Doublet JD, Gattegno B, Rossert J, Costa de Beauregard MA, Thibault P, Talbot JN. Evaluation of FDG uptake by renal malignancies (primary tumor or metastases) using a coincidence detection gamma camera. J Nucl Med 2000; 41:78-84. [PMID: 10647608] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023] Open
Abstract
UNLABELLED The aim of this study was to evaluate the usefulness of FDG scanning using an ordinary gamma camera equipped with coincidence detection (CDET) for 2 renal cancer indications: characterization and staging of renal masses before nephrectomy and search for recurrence after nephrectomy. METHODS Between September 1997 and June 1998, a whole-body scan and at least 1 tomoscintigram were obtained on 23 occasions in 22 patients (fasting for at least 6 h) using a Prism XP 2000 CDET gamma camera; scanning was begun 45 min after intravenous injection of 150-250 MBq FDG. RESULTS Postoperative histologic evidence was obtained from 13 of 16 patients who underwent FDG using a CDET gamma camera before renal surgery; 4 renal masses did not accumulate FDG (3 true-negatives, 1 false-negative), whereas 9 renal tumors accumulated FDG (8 true-positives, 1 false-positive). In the other 3 patients, only 1 extrarenal site of FDG uptake was checked and confirmed on histologic examination: a bone metastasis from renal cell carcinoma in 2 cases and lymph node metastasis from a squamous cell carcinoma (3 true-positives). The primary local and regional staging of the malignant renal tumors was accurate in the 9 patients who underwent nephrectomy (8 true-negatives, 1 true-positive). The primary distant staging was positive in 1 case (focus in the chest corresponding to a probable true-positive on follow-up). In the 7 examinations performed because of suspected recurrence of renal cell carcinoma several months after nephrectomy, metastases were visualized by FDG in 4 patients, confirmed by biopsy in 2 patients, and confirmed by conventional imaging or follow-up (or both) in 2 patients. The other 3 patients had negative FDG scans, corresponding to probable true-negative results on follow-up. CONCLUSION FDG using a CDET gamma camera can be used effectively for the staging and restaging of renal tumors and might be useful for characterization of the primary renal tumor in doubtful cases.
Collapse
Affiliation(s)
- F Montravers
- Services de Médecine Nucléaire, Hôpital Tenon, Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Abstract
PURPOSE Osteonecrosis of the hyoid bone is an uncommon disease that has only been described occasionally in the literature. MATERIALS AND METHODS We report 3 cases of osteonecrosis of the hyoid bone after radiation therapy for carcinoma at various sites in the head and neck region. RESULTS Imaging computed tomography (CT) scans were performed for all 3 cases and did aid in the diagnosis. In 1 case, a 201thallium scintigraphy and a bone scan (99mtechnetium-diphosphonate) were performed and this confirmed the diagnosis of osteoradionecrosis. CONCLUSION Osteoradionecrosis of the hyoid bone may be misdiagnosed as recurrent neoplasm. Although recurrent or persistent neoplastic disease must initially be ruled out, it is subsequently important to correctly identify osteonecrosis of the hyoid bone, because its surgical treatment is simple and the prognosis is good.
Collapse
Affiliation(s)
- G Monceaux
- Department of Otolaryngology and Head and Neck Surgery, Tenon Hospital, Faculty of Medicine Saint Antoine, University Paris VI, France
| | | | | | | | | | | |
Collapse
|
47
|
Montravers F, Rousseau C, Doublet JD, Gattengo B, Allard S, Fouret P, Bernaudin JF, Thibault P, Talbot JN. In vivo inaccessibility of somatostatin receptors to 111In-pentreotide in primary renal cell carcinoma. Nucl Med Commun 1998; 19:953-61. [PMID: 10234675 DOI: 10.1097/00006231-199810000-00005] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The presence of somatostatin receptors on human renal cell carcinomas in surgically removed kidneys has been demonstrated by autoradiography. The aim of this study was to detect to in vivo presence of somatostatin receptors in primary renal tumours and their possible metastases before surgery, using 111In-pentreotide scintigraphy. 201Tl was used as a sensitive tumour-seeking agent with blood flow-dependent uptake. Fifteen patients were imaged before surgical removal of the renal tumour. Thirteen tumours were malignant. The large tumours (more than 4 cm in diameter) did not accumulate 111In-pentreotide or 201Tl. In contrast, the single small tumour accumulated both tracers. A scalp skin metastasis was demonstrated in one patient by 201Tl and 111In-pentreotide uptake. In one case, known lung metastases were visualized with both 201Tl and 111In-pentreotide, but the lung metastases of another three patients as well as one case of epidural metastasis were not identified. In one patient with a photopaenic lesion, positive labelling of the surgically removed tumour was demonstrated by in vitro autoradiography. Somatostatin receptor scintigraphy with 111In-pentreotide appears to have little value for the detection of metastases in patients with renal cell carcinoma, as some metastases (especially those of the lungs) were missed. The absence of 111In-pentreotide uptake by large primary tumours is an interesting finding, suggesting inaccessibility of these very large tumours to drugs.
Collapse
Affiliation(s)
- F Montravers
- Service de Médecine Nucléaire, Hôpital Tenon, Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Montravers F, Younsi N, Rousseau C, Philippe C, Seddiki M, Uzan S, Izrael V, Talbot JN. Comparison of bone scanning and CA 15-3 serum concentration in the follow-up of breast cancer. Anticancer Res 1997; 17:1683-6. [PMID: 9179218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The follow-up bone scans (BS) of 158 women with breast cancer and without known bone metastases were reviewed and compared with serum CA 15-3 concentration. Ninety-three BS were systematic (normal serum CA 15-3) and 3 corresponded to proven bone metastases. Sixty-five BS were motivated:-by isolated bone pain (20 BS. 1 corresponding to metastases),-by bone pain and signs of progression of the disease (11 BS. 7 corresponding to metastases: elevated serum CA 15-3 except in one case), by known visceral metastases (20 BS. 6 corresponding to metastases with elevated serum CA 15-3), by an isolated increase of serum CA 15-3 (7 BS. 4 corresponding to metastasis) by local recurrence (7 BS. 1 corresponding to metastasis). These results show that bone metastases were diagnosed in 6 patients whose serum CA 15-3 concentration was normal. We conclude that the existence of normal tumor markers is not sufficient to exclude the possibility of bone metastases.
Collapse
|
49
|
Montravers F, Ricard M, Lumbroso J, Di Paola M, Schlumberger M, Parmentier C, Di Paola R. Digital superimposition of CT and positive SPECT tumor images. Phantom study and clinical applications. Clin Nucl Med 1997; 22:151-7. [PMID: 9067667 DOI: 10.1097/00003072-199703000-00003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Digital superimposition of SPECT and CT data was evaluated in a phantom and then applied to patient data. Seven patients were studied. Six patients had pheochromocytomas as evidenced by I-131 or I-123 MIBG localization and one had ovarian cancer imaged by In-111 OC125 MoAb. Anatomic or skin landmarks identified the level of each SPECT transaxial slice. Both SPECT and CT image data sets were transferred to a minicomputer connected to an image processor. Afterwards, a scaled, rotated and translated realignment was performed. Data for each modality were coded in different primary colors and then superimposed. Superimposition of phantom data was checked for the absence of distortion of pinpoint and large structures. For suspected tumor sites, superimposition of the patients' slices were allowed to check for matching SPECT and CT abnormalities to localize a SPECT abnormality without a corresponding CT lesion or to distinguish SPECT abnormalities from those seen on CT. In one case, the technique failed because of very low I-131 MIBG-tumor uptake. The superimposition decreases false positives in SPECT and both false negatives or false positives in CT.
Collapse
|
50
|
Montravers F, Coutris G, Sarda L, Mensch B, Talbot JN. Utility of thallium-201 and iodine-123 metaiodobenzylguanidine in the scintigraphic detection of neuroendocrine neoplasia. Eur J Nucl Med 1993; 20:1070-7. [PMID: 8287875 DOI: 10.1007/bf00173485] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Metaiodobenzylguanidine (MIBG) is a specific marker for neuroendocrine tumours, such as phaeochromocytoma, neuroblastoma, medullary thyroid cancer (MTC) and paraganglioma, but it suffers in some cases (especially in MTC) from a lack of sensitivity. Thallium is a well-known marker of cellularity with a great sensitivity and a lack of specificity. In order to determine whether the association of these two markers is able to improve the detection of neuroendocrine lesions, 137 scintigraphic examinations using MIBG and thallium were performed in 101 patients referred for suspicion or follow-up of neuroendocrine tumours. Thallium chloride was first injected (1 MBq/kg), images being acquired about 20 min after injection; 123I-MIBG (4 MBq/kg) was then injected and images acquired 5 and 24 h later. In patients with phaeochromocytoma or neuroblastoma, thallium scintigraphy appeared of little help since no tumoural site was discovered by thallium accumulation alone. In contrast, thallium examination seemed of interest in the detection of paraganglioma and MTC, the association of the two radiopharmaceuticals increasing the number of detected sites.
Collapse
Affiliation(s)
- F Montravers
- Faculté, de Médecine Saint Antoine, Paris, France
| | | | | | | | | |
Collapse
|